The FDA granted approval late Friday for Tarceva (erlotinib) as a maintenance therapy for non-small-cell lung cancer patients, a decision that defied a negative 12-to-1 panel vote last year but is likely to offer only a modest boost to sales of the drug from OSI Pharmaceuticals Inc. and Genentech Inc./Roche AG. (BioWorld Today) Read More
